Cargill’s EpiCor postbiotic ingredient health claims licensed by Health Canada
The claims focus on support for immune and digestive health.
Cargill (Minneapolis) announced that Health Canada has licensed 10 health claims for the company’s EpiCor postbiotic ingredient as a Natural Health Product. The health claims focus on support for immune and digestive health.
The claims are based on a daily EpiCor dose of 500 mg in adults aged 18 and older and are backed by more than a dozen published clinical studies, the company says. The claims include:
- Helps to reduce the incidence of cold and flu symptoms (during the winter months)
- Helps to reduce the symptoms of seasonal allergies such as nasal stuffiness/congestion
- Helps relieve nasal stuffiness/congestion associated with seasonal allergies
- Helps to maintain immune function
- An antioxidant that helps to support good health
- Source of antioxidant(s)/provides antioxidant(s)
- Helps support intestinal/gastrointestinal health
- Helps to improve occasional mild to moderate bloating/distension
- Helps to improve occasional mild to moderate feeling of fullness
- Occasionally helps to improve stool consistency
In a press release, Justin Green, PhD, director of scientific affairs for EpiCor, added, “This news, from one of the world’s leading health agencies, affirms the significant body of science behind EpiCor…”
Brightseed launches clinically validated ingredient, Bio Gut Core, to support gut barrier function
May 21st 2025The low-dose, easy-to-formulate ingredient is a proprietary blend of two bioactives – N-trans caffeoyltyramine (NCT) and N-trans feruloyltyramine (NFT) – which were discovered by the company’s Forage AI platform.
A country-by-country blueprint for nutraceutical success in Europe
May 20th 2025The European nutraceutical market is growing rapidly, but the continent is not a monolith when it comes to consumer trends and product innovation. This article is a blue-print for what nutraceutical success looks like in different European countries.
